Bernstein analyst Lee Hambright lowered the firm’s price target on Medtronic (MDT) to $93 from $97 and keeps an Outperform rating on the shares as ...

Bernstein raised the firm’s price target on Stryker (SYK) to $425 from $410 and keeps an Outperform rating on the shares as part of a broader ...

Seer Medical’s directors voted to enter voluntary administration late last year, and Pitcher Partners was appointed as ...

Bernstein raised the firm’s price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader ...

Bernstein raised the firm’s price target on DexCom (DXCM) to $89 from $86 and keeps an Outperform rating on the shares as part of a broader ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

FlowBeams, creator of the BoldJet needle-free injection showcased itsbreakthrough medtech technology at CES 2025.The company’s innovative needle-free injection ...

Boston Scientific stock popped Wednesday after the medtech giant agreed to full acquire Bolt Medical for up to $900 million.

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

Johnson & Johnson MedTech announced today that it temporarily paused all U.S. Varipulse external evaluations and cases.